158 related articles for article (PubMed ID: 18444839)
1. Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients.
Lapadula G; Costarelli S; Quiros-Roldan E; Calabresi A; Izzo I; Carosi G; Torti C
Clin Infect Dis; 2008 Apr; 46(7):1127-9. PubMed ID: 18444839
[No Abstract] [Full Text] [Related]
2. Safety and efficacy of tenofovir/emtricitabine plus nevirapine in HIV-infected patients.
Labarga P; Medrano J; Seclen E; Poveda E; Rodriguez-Novoa S; Morello J; de Mendoza C; Vispo E; Soriano V
AIDS; 2010 Mar; 24(5):777-9. PubMed ID: 20168201
[TBL] [Abstract][Full Text] [Related]
3. Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study).
Podzamczer D; Andrade-Villanueva J; Clotet B; Taylor S; Rockstroh JK; Reiss P; Domingo P; Gellermann HJ; de Rossi L; Cairns V; Soriano V
HIV Med; 2011 Jul; 12(6):374-82. PubMed ID: 21518220
[TBL] [Abstract][Full Text] [Related]
4. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
Rey D; Hoen B; Chavanet P; Schmitt MP; Hoizey G; Meyer P; Peytavin G; Spire B; Allavena C; Diemer M; May T; Schmit JL; Duong M; Calvez V; Lang JM
J Antimicrob Chemother; 2009 Feb; 63(2):380-8. PubMed ID: 19036752
[TBL] [Abstract][Full Text] [Related]
5. Combination antiretroviral therapy with tenofovir, emtricitabine or lamivudine, and nevirapine.
Redfield RR; Morrow JS
Clin Infect Dis; 2008 Oct; 47(7):984-5. PubMed ID: 18778234
[No Abstract] [Full Text] [Related]
6. Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1.
; Arrivé E; Chaix ML; Nerrienet E; Blanche S; Rouzioux C; Coffie PA; Kruy Leang S; McIntyre J; Avit D; Srey VH; Gray G; N'Dri-Yoman T; Diallo A; Ekouévi DK; Dabis F
AIDS; 2009 Apr; 23(7):825-33. PubMed ID: 19307941
[TBL] [Abstract][Full Text] [Related]
7. [First line therapy. Tenofovir DF/emtricitabine--the potent backbone].
MMW Fortschr Med; 2008 Apr; 150 Spec No 1():12-4. PubMed ID: 19024908
[No Abstract] [Full Text] [Related]
8. Clinical experience with nevirapine combined with tenofovir plus emtricitabine or lamivudine-containing regimens in HIV-infected subjects.
Smith DE; Chan DJ; Maruszak H; Jeganathan S
Int J STD AIDS; 2011 Apr; 22(4):228-30. PubMed ID: 21515757
[TBL] [Abstract][Full Text] [Related]
9. Viral load decay in antiretroviral-naïve patients receiving once-daily tenofovir and emtricitabine plus twice-daily nevirapine.
Amoroso A; Gilliam BL; Talwani R; Boyce C; Redfield RR; Davis CE
HIV Clin Trials; 2009; 10(5):320-3. PubMed ID: 19906624
[TBL] [Abstract][Full Text] [Related]
10. Comment on: High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
Parienti JJ
J Antimicrob Chemother; 2009 May; 63(5):1080; author reply 1080-1. PubMed ID: 19158108
[No Abstract] [Full Text] [Related]
11. The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients.
Chetchotisakd P
Expert Rev Anti Infect Ther; 2009 Sep; 7(7):801-5. PubMed ID: 19735222
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of once-daily nevirapine dosing: a multicohort study.
Calmy A; Vallier N; Nguyen A; Lange JM; Battegay M; de Wolf F; Reiss P; Lima VD; Hirschel B; Hogg RS; Yip B; Montaner JS; Wit FW; ; ;
Antivir Ther; 2009; 14(7):931-8. PubMed ID: 19918097
[TBL] [Abstract][Full Text] [Related]
13. A new drug combination therapy for treatment-naive patients with HIV-1 infection, consisting of raltegravir, emtricitabine and tenofovir disoproxil fumarate.
De Clercq E
Expert Opin Pharmacother; 2009 Dec; 10(17):2935-7. PubMed ID: 19929712
[TBL] [Abstract][Full Text] [Related]
14. A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients.
Dejesus E; Mills A; Bhatti L; Conner C; Storfer S
Int J Clin Pract; 2011 Dec; 65(12):1240-9. PubMed ID: 21999631
[TBL] [Abstract][Full Text] [Related]
15. 96-week CASTLE data show similar efficacy results.
AIDS Patient Care STDS; 2008 Nov; 22(11):918. PubMed ID: 19043840
[No Abstract] [Full Text] [Related]
16. Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection.
Elion R; Cohen C; Gathe J; Shalit P; Hawkins T; Liu HC; Mathias AA; Chuck SL; Kearney BP; Warren DR;
AIDS; 2011 Sep; 25(15):1881-6. PubMed ID: 21811136
[TBL] [Abstract][Full Text] [Related]
17. Maternal and nenonatal tenofovir and emtricitabine to prevent vertical transmission of HIV-1: tolerance and resistance.
; Arrivé E; Chaix ML; Nerrienet E; Blanche S; Rouzioux C; Avit D; Kruy LS; McIntyre J; Say L; Gray G; Ekouévi DK; Dabis F
AIDS; 2010 Oct; 24(16):2481-8. PubMed ID: 20827166
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients.
Bonora S; Gonzalez de Requena D; D'Avolio A; Calcagno A; Tettoni M; Siccardi M; Baietto L; Simiele M; Trentini L; Di Perri G
Antivir Ther; 2011; 16(4):499-504. PubMed ID: 21685537
[TBL] [Abstract][Full Text] [Related]
19. Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients.
Vrouenraets SM; Wit FW; Fernandez Garcia E; Moyle GJ; Jackson AG; Allavena C; Raffi F; Jayaweera DT; Mauss S; Katlama C; Fisher M; Slama L; Hardy WD; Dejesus E; van Eeden A; Reiss P;
HIV Med; 2011 Nov; 12(10):620-31. PubMed ID: 21819530
[TBL] [Abstract][Full Text] [Related]
20. Number of daily pills, dosing schedule, self-reported adherence and health status in 2010: a large cross-sectional study of HIV-infected patients on antiretroviral therapy.
Gianotti N; Galli L; Bocchiola B; Cahua T; Panzini P; Zandonà D; Salpietro S; Maillard M; Danise A; Pazzi A; Lazzarin A; Castagna A
HIV Med; 2013 Mar; 14(3):153-60. PubMed ID: 22994659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]